Welcome to our dedicated page for Abcellera Biologics news (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on Abcellera Biologics stock.
AbCellera Biologics (NASDAQ: ABCL) operates at the intersection of biotechnology and drug discovery, making its news feed particularly relevant for investors tracking the antibody therapeutics space. As a platform company that partners with pharmaceutical giants to discover monoclonal antibodies, AbCellera's announcements often signal broader trends in the therapeutics pipeline landscape.
News coverage for ABCL typically centers on partnership announcements and program milestones. When AbCellera discloses new collaborations or reports that partner programs have advanced to new clinical phases, these developments directly impact the company's future milestone and royalty revenue streams. Each clinical trial progression represents both validation of the discovery platform and potential future income.
Quarterly earnings releases reveal how AbCellera's partnership economics translate into financial performance. Beyond headline numbers, these reports detail the status of partner programs, new agreements signed, and updates on the company's proprietary internal pipeline. For a platform-based biotech, understanding the partnership pipeline is essential context.
Clinical trial updates feature prominently in AbCellera's news flow. The company's internal programs generate announcements around trial initiations, interim data readouts, and regulatory interactions. Additionally, positive developments from partner programs—where AbCellera discovered the underlying antibody—often merit disclosure given milestone payment implications.
Patent and intellectual property news matters for platform companies. AbCellera's microfluidic technology represents a core competitive advantage, and developments related to patent protection or technology licensing can affect the company's market position.
Bookmark this page to follow AbCellera's developments as the company advances its antibody discovery platform and expands its therapeutic pipeline.
AbCellera (ABCL) has announced its participation in two upcoming investor conferences in September 2024. The company will present at the Wells Fargo Healthcare Conference on September 5 at 12:00 p.m. Pacific Time, and the Cantor Global Healthcare Conference on September 17 at 8:30 a.m. Pacific Time.
Investors and interested parties can access live audio webcasts of both presentations through links that will be available on AbCellera's Investor Relations website. Replays of the webcasts will also be accessible through the same links after the presentations conclude.
These conferences provide AbCellera with opportunities to showcase its latest developments and engage with the investment community, potentially impacting its stock performance and market perception.
AbCellera (Nasdaq: ABCL) announced its financial results for Q2 2024.
Revenue decreased to $7.3 million from $10.1 million in Q2 2023, with research fees contributing $5.5 million and milestone payments $1.5 million.
Expenses rose overall, with R&D expenses at $40.9 million (up from $36.5 million), G&A expenses at $20.2 million (up from $15.5 million), and S&M expenses at $3.1 million (down from $3.8 million).
Net Loss increased to $36.9 million, or $(0.13) per share, compared to $30.5 million, or $(0.11) per share, in Q2 2023.
Liquidity remains strong at $697.6 million, with $220 million in available non-dilutive funding, bringing total liquidity to over $900 million.
Key developments include clinical trial applications for ABCL635 and ABCL575 expected in Q2 2025, the initiation of three T-cell engager programs, and an expanded partnership with Lilly.
AbCellera (Nasdaq: ABCL) has expanded its collaboration with Eli Lilly to develop antibody medicines for immunology, cardiovascular disease, and neuroscience programs. This builds on their successful partnership from March 2020, which included eight de novo programs and led to emergency use authorization for two COVID-19 antibody therapies. Under the new agreement, Lilly gains rights to develop and commercialize resulting therapeutic antibodies, while AbCellera receives an upfront payment, research payments, and potential milestone payments and royalties.
AbCellera's CEO, Carl Hansen, expressed excitement about deepening their partnership with Lilly, aiming to increase their impact on patients across multiple therapeutic areas. The expansion demonstrates the success of their initial collaboration and AbCellera's capabilities in antibody discovery and development.
AbCellera (Nasdaq: ABCL) will unveil its second quarter 2024 financial results on August 6, 2024. The company has scheduled an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. Interested parties can access the live audio webcast via a link on AbCellera's Investor Relations website, where a replay will also be available post-conference.
AbCellera (Nasdaq: ABCL) announced today that its executives will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, at 12:20 p.m. PT (3:20 p.m. ET). The presentation will be available via a live audio webcast on AbCellera's Investor Relations website, with a replay accessible afterward.
AbCellera reported Q1 2024 financial results with total revenue of $10.0 million and a net loss of $40.6 million. The company announced new collaborations, presented TCE program data at a cancer research meeting, and initiated partner programs. Key metrics show growth in partner programs and molecules in the clinic. Despite a decrease in revenue, AbCellera maintains strong liquidity of nearly $1 billion.
AbCellera, Viking Global Investors, and ArrowMark Partners have collaborated to launch new biotech companies focusing on advancing antibody drug programs. The partnership aims to create assets in the area of immunology, with Viking and ArrowMark overseeing program selection and funding, while AbCellera leverages its expertise in discovering and developing antibody medicines. Successful programs will lead to the creation of new companies, with AbCellera participating as an equity founding partner.
FAQ
What is the current stock price of Abcellera Biologics (ABCL)?
What is the market cap of Abcellera Biologics (ABCL)?
